Monoclonal Antibodies to the V2 Domain of MN-rgp120: Fine Mapping of Epitopes and Inhibition of α4β7 Binding
暂无分享,去创建一个
Gerald R. Nakamura | Aaron L. Vollrath | G. Nakamura | P. Berman | Phillip W. Berman | A. Vollrath | Dora P. A. J. Fonseca | Sara M. O’Rourke | Dora Fonseca | S. O’Rourke
[1] E. Callaway. Clues emerge to explain first successful HIV vaccine trial , 2011 .
[2] A. Pinter,et al. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site , 1996, Journal of virology.
[3] Dennis R. Burton,et al. A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals , 2010, PLoS pathogens.
[4] R. Belshe,et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. , 1994, JAMA.
[5] Pham Phung,et al. Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.
[6] N. Sullivan,et al. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120 , 1993, Journal of virology.
[7] P. Gilbert,et al. Recombinant gp120 Vaccine-Induced Antibodies Inhibit Clinical Strains of HIV-1 in the Presence of Fc Receptor-Bearing Effector Cells and Correlate Inversely with HIV Infection Rate1 , 2007, The Journal of Immunology.
[8] L. Lasky,et al. Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus , 1985, Nature.
[9] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[10] E. Butcher,et al. Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. , 1994, Journal of immunology.
[11] Bette Korber,et al. Structure of a V3-Containing HIV-1 gp120 Core , 2005, Science.
[12] L. Stamatatos,et al. An Envelope Modification That Renders a Primary, Neutralization-Resistant Clade B Human Immunodeficiency Virus Type 1 Isolate Highly Susceptible to Neutralization by Sera from Other Clades , 1998, Journal of Virology.
[13] T. Wrin,et al. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. , 1996, The Journal of infectious diseases.
[14] S. Zolla-Pazner,et al. The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection , 2004, Journal of Virology.
[15] Reed J. Harris,et al. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. , 1990, The Journal of biological chemistry.
[16] T. Kepler,et al. Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors , 2011, Journal of Virology.
[17] M. Reitz,et al. Envelope sequences of two new United States HIV-1 isolates. , 1988, Virology.
[18] T. Wrin,et al. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. , 1997, The Journal of infectious diseases.
[19] D. Ho,et al. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 , 1992, Journal of virology.
[20] D. Burton,et al. GP120: target for neutralizing HIV-1 antibodies. , 2006, Annual review of immunology.
[21] L. Stamatatos,et al. The V1, V2, and V3 Regions of the Human Immunodeficiency Virus Type 1 Envelope Differentially Affect the Viral Phenotype in an Isolate-Dependent Manner , 2005, Journal of Virology.
[22] R. Kaul,et al. The integrin α4β7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1 , 2009, Proceedings of the National Academy of Sciences.
[23] T. Hope,et al. Human Immunodeficiency Virus Type 1 Is Trapped by Acidic but Not by Neutralized Human Cervicovaginal Mucus , 2009, Journal of Virology.
[24] Jerome A. Zack,et al. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure , 1990, Cell.
[25] R. Belshe,et al. Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. , 1998, AIDS research and human retroviruses.
[26] Punnee Pitisuttithum,et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.
[27] P. Nakane. RECENT PROGRESS IN THE PEROXIDASE‐LABELED ANTIBODY METHOD * , 1975, Annals of the New York Academy of Sciences.
[28] L. Stamatatos,et al. Identification of a New Quaternary Neutralizing Epitope on Human Immunodeficiency Virus Type 1 Virus Particles , 2005, Journal of Virology.
[29] Allan C. deCamp,et al. Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial , 2013, PloS one.
[30] T. Kunkel. Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[31] Timothy Cardozo,et al. Structure–function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design , 2010, Nature Reviews Immunology.
[32] Kenneth H Mayer,et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.
[33] Hasan Ahmed,et al. Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials , 2012, The Journal of infectious diseases.
[34] L. Morris,et al. Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop , 2011, Journal of Virology.
[35] T. Wrin,et al. Mutation at a Single Position in the V2 Domain of the HIV-1 Envelope Protein Confers Neutralization Sensitivity to a Highly Neutralization-Resistant Virus , 2010, Journal of Virology.
[36] Hui Li,et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.
[37] J. McKeating,et al. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain , 1995, Journal of virology.
[38] J. Moore,et al. A monoclonal antibody to the CDR-3 region of CD4 inhibits soluble CD4 binding to virions of human immunodeficiency virus type 1 , 1993, Journal of virology.
[39] E. Engleman,et al. Evidence that T cell activation is required for HIV-1 entry in CD4+ lymphocytes. , 1989, Journal of immunology.
[40] M. Champe,et al. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1 , 1992, Journal of virology.
[41] Michael G Hudgens,et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. , 2005, The Journal of infectious diseases.
[42] P. Berman. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. , 1998, AIDS research and human retroviruses.
[43] E. Butcher,et al. Structure-function analysis of the integrin beta 7 subunit: identification of domains involved in adhesion to MAdCAM-1. , 1997, Journal of immunology.
[44] M. Stevenson,et al. HIV‐1 replication is controlled at the level of T cell activation and proviral integration. , 1990, The EMBO journal.
[45] Jerome H. Kim,et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.
[46] Guido Ferrari,et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.
[47] M. Pérez‐Losada,et al. Phylodynamics of HIV-1 from a Phase-III AIDS Vaccine Trial in North America , 2009, Molecular biology and evolution.
[48] J. Sodroski,et al. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein , 1995, Journal of virology.
[49] G. Nakamura,et al. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1 , 1993, Journal of virology.
[50] J. Sodroski,et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.
[51] D. Montefiori,et al. Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays , 2004, Current protocols in immunology.
[52] W. Carter,et al. B Lymphocyte Fibronectin Receptors: Expression and Utilization , 1991, Scandinavian journal of immunology.
[53] A. van der Eb,et al. A new technique for the assay of infectivity of human adenovirus 5 DNA. , 1973, Virology.
[54] T. Wrin,et al. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. , 1999, Virology.
[55] S. Zolla-Pazner,et al. The C108g Epitope in the V2 Domain of gp120 Functions as a Potent Neutralization Target When Introduced into Envelope Proteins Derived from Human Immunodeficiency Virus Type 1 Primary Isolates , 2005, Journal of Virology.
[56] Barney S. Graham,et al. Neutralizing Antibodies to HIV-1 in Seronegative Volunteers Immunized With Recombinant gp 120 From the MN Strain of HIV-1 , 1994 .
[57] Monoclonal antibodies to the extracellular domain of HIV-1IIIB gp160 that neutralize infectivity, block binding to CD4, and react with diverse isolates. , 1992, AIDS research and human retroviruses.
[58] J. Sodroski,et al. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 , 1994, Journal of virology.
[59] Young Do Kwon,et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 , 2011, Nature.